Dec 6, 2006|
Pharma: A dull November but...
November 2006 was a lacklustre month for the pharma sector with the BSE Healthcare index having under performed the BSE-Sensex. While the performance of most of the pharma stocks under our coverage left a lot to be desired, certain stocks bucked the trend and captured the investors' fancy. In this write-up, we shall take a look at the top four performers (under our coverage), which have outperformed the BSE Healthcare index and the reasons behind this buoyancy.
Glenmark: Glenmark's gains of 35% in the month of November have been nothing short of meteoric. The September quarter results were robust with the company's core businesses having recorded a strong growth and beating the management's expectations. The company's agreement with Merck for out-licensing the former's anti-diabetic molecule for milestone payments of around 190 m euros further fueled the optimism in the stock.
Sun Pharma: Investors continued to flock to Sun Pharma, which posted gains of 11% during November. The company has been relatively conservative in charting its growth path in comparison to its more aggressive peers Ranbaxy and Dr.Reddy's and this strategy seems to have reaped benefits. The company's focus on speciality and niche product segments have entrenched its hold over the domestic market and is expected to stand the company in good stead in the regulated markets as well. Besides this, the company has reported strong performances in the US market too through its subsidiary Caraco, despite the highly competitive conditions in the US generics market.
Nicholas Piramal: Nicholas Piramal continued to gain ground in November registering gains of 4.6%. The optimism with regards to the stock can be attributed to the increasing contribution from its custom manufacturing business (with global innovator companies) to total revenues. Nicholas' strategy involves partnering with global pharma majors to drive its custom pharma sales rather than focus on generics. The company has been active on the acquisition front too. Besides the Avecia acquisition in December 2005, Nicholas Piramal acquired Pfizer's Morpeth facility in the UK to further bolster its custom manufacturing revenues.
Biocon: Biocon registered gains of around 4% during November. The company had recently launched its anti-cancer drug 'BIOMAb EGFR' in the Indian market and this seemingly spurred the interest in the stock. Besides this, 2HFY07 is expected to be better for Biocon (as compared to 1HFY07) as the company begins its bulk drug supplies of 'Pravastatin' and 'Simvastatin' in the US market post the expiry of the 180-day exclusivity. Having said that, a larger chunk of Biocon's revenues still come from statins and pricing pressure is expected to affect realisations from these two drugs in the long-term. Thus, the company's focus on other biologic products will be the key in driving growth going forward.
While we have commented on the performance for the month of November, investors need to follow a long-term approach while investing in pharma stocks. Also, the investment philosophy in this sector has to be based on the growth prospects of the sector, the ability of a company to capitalise on these growth opportunities, strong management, consistency in profitability and the ability to innovate in this highly dynamic industry. Thus, investors need to research each company thoroughly and should certainly not base their decisions on a single event (for instance, the success or failure to win a patent challenge for a drug).
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
Aug 18, 2017
Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407